2. Academic Validation
  3. Successful kinase bypass with new acyclovir phosphoramidate prodrugs

Successful kinase bypass with new acyclovir phosphoramidate prodrugs

  • Bioorg Med Chem Lett. 2008 Aug 1;18(15):4364-7. doi: 10.1016/j.bmcl.2008.06.069.
Christopher McGuigan 1,  Marco Derudas,  Joachim J Bugert,  Graciela Andrei,  Robert Snoeck,  Jan Balzarini
Affiliations

Affiliation

  • 1 Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, UK. mcguigan@cardiff.ac.uk
PMID: 18614365 DOI: 10.1016/j.bmcl.2008.06.069
Abstract

Novel phosphoramidates of acyclovir have been prepared and evaluated in vitro against acyclovir-sensitive and -resistant herpes simplex virus (HSV) types 1 and 2 and varicella-zoster virus (VZV). Unlike the parent nucleoside these novel phosphate prodrugs retain Antiviral potency versus the ACV-resistant virus strain, suggesting an efficient bypass of the viral thymidine kinase.

Figures